Duncan Bassett

Duncan Bassett is Professor of Endocrinology at Imperial College London and is a consultant physician at Hammersmith Hospital specialising in metabolic bone disease. His research focuses on understanding the fundamental cellular and molecular mechanisms that underlie skeletal development, maintenance and repair and their dysregulation in chronic degenerative diseases such as osteoporosis and osteoarthritis. He also has a longstanding interest in thyroid hormone action and particularly its role in the developing and adult skeleton.
http://www.imperial.ac.uk/people/d.bassett

Nick Bishop

Nick Bishop is Professor of Paediatric Bone Disease at the University of Sheffield. He is Co-Chief Investigator on the MOI – A study, looking at repurposing losartan in adults and older adolescents with osteogenesis imperfecta and global chief investigator for the Ultragenyx-sponsored studies of setrusumab in children and young adults with osteogenesis imperfecta. He is Associate Director of the Versus Arthritis Experimental Arthritis Treatment Centre for Children, a Trustee of the Brittle Bone Society, and an Honorary Fellow of the Royal College of Paediatrics and Child Health.

Alison Boyce

Alison Boyce, MD is a Paediatric Endocrinologist and Chief of the Metabolic Bone Disorders Unit in the National Institute of Dental and Craniofacial Research, National Institutes of Health. The goal of her work is to enhance health and well-being for children with skeletal disorders by developing novel tools and treatments informed by pathophysiologic studies. She leads investigations in fibrous dysplasia/McCune-Albright syndrome, a rare disease affecting the bone and endocrine systems, and has characterized many aspects of this disorder and its treatment. Dr Boyce is a faculty member in the NIH Endocrinology fellowship training program. She is a member of the Fibrous Dysplasia/McCune-Albright Syndrome International Consortium and serves as Chair of the Medical Advisory Committee to the FD/MAS Alliance.

Björn Busse

Björn Busse is Full Professor of Biomedical Sciences and Medical Technology at the University Medical Center Hamburg, Germany. He is head of the Interdisciplinary Center for Interface Research in Hamburg (ICCIR). With expertise in skeletal imaging, biomechanics, and bone quality analyses, he earned his Ph.D. with honors from the Free and Humboldt University Berlin / Charité, University Medicine Berlin. His research focuses on bone imaging, mineralization, and fracture mechanisms, addressing bone quality in aging, osteoporosis, osteomalacia, and other conditions. He gained post-doc experience at the Lawrence Berkeley National Laboratory (LBNL) and the University of California, Berkeley. With over 150 research publications, he has received prestigious awards including the 'John Haddad Young Investigator Award' from the American Society of Bone and Mineral Research and the 'von Recklinghausen Prize' from the German Society of Endocrinology.

Tom Carpenter

Thomas Carpenter is Professor of Paediatrics and Professor of Orthopaedics and Rehabilitation at the Yale School of Medicine. He received his medical degree and underwent paediatrics training at the University of Alabama. While training in endocrinology at Boston Children's Hospital, he began a career-long involvement in clinical research focused on metabolic bone disorders. He has been at Yale for over 35 years, initiating the Paediatric Endocrinology Fellowship Program and directing it for nearly 20 years. Dr. Carpenter founded Yale's interdisciplinary Paediatric Metabolic Bone Disease clinic, and the Yale Center for X-Linked Hypophosphatemia, a setting for the study and clinical care of patients with XLH and related conditions. He has authored over 200 articles, reviews, and book chapters related to metabolic bone disease in children. He is a member of the Endocrine Society, American Society for Bone and Mineral Research, and is the immediate Past-President of the Paediatric Endocrine Society.



Catherine Chaussain

Catherine Chaussain (DDS-PhD) is the director of the “Orofacial Pathologies, Imaging and Biotherapies” laboratory at the Dental School of UPCité. As a PhD student, she worked on 3D culture models of gingival stem cells to study the wound healing process. As a post-doctoral fellow, she identified pathological MEPE-ASARM-derived peptides in human X-linked hypophosphatemia tooth dentin. In 2007, she did a postdoctoral fellowship at the University of Illinois Chicago (UIC) with Prof Anne George. There she worked on the degradation of phosphorylated proteins by MMPs and used the cleavage products to induce tooth/bone regeneration. As head of the BRIO laboratory, she developed new research themes using tooth to study biomineralization in the context of rare disorders related to mineral metabolism. At the APHP hospital, she is the head of the dental unit of the French reference centre for patients with rare disorders related to mineral metabolism (OSCAR network, ERN BOND).

Roberto Civitelli

Roberto Civitelli, MD is a Professor of Medicine and serves as the Chief of the Division of Bone and Mineral Disease at Washington University in St. Louis. Hailing from Siena, Italy, Dr. Civitelli has been affiliated with the Division of Bone and Mineral Diseases since 1985, shaping its trajectory as a leading research, education and patient care center. As a physician-scientist, he has published over 200 original articles, reviews and book chapters and leads a dynamic bone biology program, supported by the NIH for over 30 years. As a clinician, Dr. Civitelli provides specialized treatment for individuals with metabolic bone disorders. He has held leadership positions in ASBMR, including President (2013-2014), and other international professional organizations. He has served as Editor-in-Chief of Calcified Tissue International (2001-2013) and the Journal of Bone and Mineral Research (2018-2022). His contributions as researcher and mentor have been acknowledged by many prestigious awards.

Antonella Forlino

Dr. Antonella Forlino obtained her Degree in Biological Science, her Doctoral Degree in Biochemistry and her Speciality Degree in Genetic at the University of Pavia, Pavia, Italy. She spent 5 years as post doctoral fellow at the National Institute of Health, Bethesda, USA, and became later on researcher and Associate professor at the Dept of Molecular Medicine, Section of Biochemistry, at the University of Pavia where she is now working as Full professor. Since October 2019 she is Vice-Rector for the Internazionalization and President of the Center for Global Strategic Engagement.

Her research activity had been and is focused on the molecular, biochemical, and functional study of genetic diseases of the connective tissue, in particularly the brittle bone disease Osteogenesis Imperfecta (OI).

She developed and characterized the first non lethal knock in murine model for OI and used this model for investigating OI phenotypic variability using proteomic and transcriptomic approaches and to develop novel cell/gene therapy and repositioning drug strategy. She generated and characterized other murine models and more recently she activated a D.Rerio facility at the University of Pavia to create by CRISPR/Cas gene editing, to characterize and to use for drug screening several zebrafish models of skeletal dysplasias.

Wolfgang Högler

Professor Wolfgang Högler is Chair-Chief of Paediatrics and head of paediatric endocrinology at the Johannes Kepler University in Linz, Austria. He received paediatric & endocrine training at the Medical University Innsbruck, Austria and the Children’s Hospital at Westmead, Sydney, Australia, followed by clinical-academic appointments in Innsbruck, Austria and Birmingham, UK.

Prof. Högler’s research groups focus on clinical and translational research, specifically the molecular mechanism of disease, novel diagnostic tools and clinical trials on rare bone and growth disorders such as osteogenesis imperfecta, hypophosphatasia, rickets and achondroplasia. Prof. Högler is the Co-Chair of the Global HPP registry and leads the ALPL gene variant consortium dedicated to variant classification and elucidation of the HPP disease spectrum. He conducts clinical trials and studies that investigate the public health aspects of vitamin D deficiency, the reversibility of idiopathic growth hormone deficiency and rare endocrine disorders. Prof. Högler chaired the 7th International Conference on Children's Bone Health (ICCBH) and the Global Consensus for the Prevention and Management of Rickets. He organises the ICCBH Bone School and lectures at various postgraduate paediatric endocrine seminars, and enjoys mentoring young clinical researchers and students.

Anuradha Khaldilkar

Dr. Anuradha Khadilkar is a paediatrician who has been working with children for over 30 years, of these, for the last 25 years she has been involved in research work and has been supervising /guiding Master's students, Graduate Medical students and PhD students (26 students are pursuing/ have pursued their doctoral work under her guidance). She is the Deputy Director at the Hirabai Cowasji Jehangir Medical Research Institute (HCJMRI), Jehangir Hospital, Pune and is also a Consultant Paediatrician at the Jehangir Hospital, Pune, India. She is a PhD teacher for Pune University at the Department of Health Sciences. Her research interests include childhood bone health, growth and endocrine disorders in children. She has completed over 100 research studies and has over 300 publications and 50 awards for research papers at research conferences. She has set up and is heading the Bone Density Unit at Jehangir hospital in Pune, India since 2005; this is one of the few well equipped bone units with an iDXA (GE Lunar), pQCT (Stratec) and equipment for muscle function including hand dynamometers, jumping mechanography machines, etc. Her social cause is Type 1 diabetes; with her team, she helps support 600 underprivileged children with Type 1 Diabetes.

Agnes Linglart

Agnès Linglart is Professor of Paediatrics at the Paris Saclay University and Bicêtre Hospital in France. She is the Head of the 'endocrinology and diabetes for children' department at the Bicêtre Paris Saclay Hospital, and the national coordinator of the network for rare bone diseases OSCAR, and of the Centre of Reference for Rare Disorders of Calcium and Phosphate Metabolism. Her research is focused on rare disorders that affect the bone mineralization during growth. She is also involved in teaching activities in paediatrics and endocrinology; since 2017 she is vice-dean for the Department of International Affairs of the Paris Saclay faculty of medicine. Agnès Linglart is involved as President of the French Society of Paediatrics. Professor Linglart's area of research is paediatric endocrinology, with a particular focus on rare diseases affecting the bone metabolism, calcium and phosphate homeostasis.

Craig Munns

Professor Craig Munns is the Head, Mayne Academy of Paediatrics and Director, Child Health Research Centre at The University of Queensland. He is also a Senior Medical Office Department of Endocrinology at Queensland Children's Hospital.

Prof Munns' primary clinical and research interest is the diagnosis and management of primary and secondary paediatric bone disorders. He has published widely on nutritional rickets, genetic rickets, osteoporosis and osteogenesis imperfecta. He has undertaken numerous trials of novel therapies in paediatric bone disease and their implementation into clinical practice. With colleagues in Australia and overseas, Prof Munns has developed protocols for the use of Denosumab in focal bone tumours and avascular necrosis. Prof Munns is also heavily involved in enabling clinical trials in Advanced Therapeutics, including cell and gene therapy.

Nicolas Nicolaou

Nick is a Consultant Paediatric Orthopaedic Surgeon at Sheffield Children's Hospital. He trained in London and completed Fellowship training at Sheffield Children's, Royal National Orthopaedic Hospital and Great Ormond Street Hospital as well as completing a travelling fellowship at Inselspital, Berne prior to becoming a Consultant in 2010.

His clinical interest is in the management of Osteogenesis Imperfecta, clinical research and the paediatric knee.

Keiichi Ozono

Chief, Center for Promoting Treatment of Intractable Diseases, ISEIKAI International General Hospital

EDUCATION:

1976-1982 - Osaka University Medical School, M.D.

1992 - Osaka University Medical School, Ph. D.

Professional Experience (in brief):

1982-1983 Resident, Department of paediatrics, Osaka University Hospital

1989-1991 Research Associate, Department of Paediatrics and Cell Biology (Dr. J.W. Pike), Baylor College of Medicine, Houston Tx, USA

1994-2002 Department Head, Department of Environmental Medicine, Osaka Medical Center and Research Institute for Maternal and Child Health

2002-2023 Professor, Department of Paediatrics, Osaka University, Graduate School of Medicine

PRESENT:

ISEIKAI International General Hospital

AWARDS:

1990 Young Investigator Award, American Society of Bone and Mineral Research, and Vitamin D Workshop

Young Investigator Award, The Vitamin Society of Japan

Investigator Award, Japanese Society of Bone and Mineral Metabolism

2013 Kenji Fujieda Award, Japanese Society of Paediatric Endocrinolgy

2018 Society Award, Japanese Society of Paediatric Endocrinolgy

2022 Society Award, The Japan Endocrine Society

Journals:

Journal of Bone and Mineral Research, Deputy editor, Clinical Paediatric Endocrinology and Endocrine Journal, Associate editor

Dror Paley

Dror Paley, MD, FRCSC is the CEO, Founder, and Medical Director of the Paley Orthopaedic and Spine Institute in West Palm Beach, Florida, from 2009 to present, and the Founder of the Paley European Institute in Warsaw, Poland, from 2018 to present, Paley Middle East Clinic, Abu Dhabi, UAE 2023-24 and Paley Latino Americano Institute 2024 in Medellin, Colombia.

Previously, he was the Founder and Director of the Rubin Institute for Advanced Orthopaedics, Baltimore, 2001-2009, and Professor & Chief of Pediatric Orthopedics at the University of Maryland, 1987-2001. Before that, he obtained subspecialty fellowship training in Pediatric Orthopedics, Hand Surgery, Trauma Surgery, and Limb Lengthening and Reconstruction Surgery, 1985-87. He completed his orthopedic surgery residency at the University of Toronto 1980-1985 and his internship at Johns Hopkins 1979-80. He received his medical degree from the University of Toronto Medical School, Toronto, Canada, in 1979.

Dr. Paley is internationally recognized for his expertise in limb lengthening and reconstruction. He trained under the guidance of Prof. Gavril Ilizarov during multiple visits to Kurgan, Soviet Union. Dr. Paley introduced the Ilizarov method to the US and Canada in 1987. He was the Founder and first president of the Limb Lengthening and Reconstruction Society in 1989 and of the International Limb Lengthening and Reconstruction Society in 2015. He is the recipient of numerous awards, including Gubernatorial Citation 1990, Pauwel's Medal in Clinical Biomechanics 1997, Best paper/poster award by SICOT, AAOS, POSNA, AORS; best illustrated medical textbook 2003; Health Professional of the Year 2011, Health Hero of the Year 2013, Florida Most Influential Business Leader 2019, 20, 21, 22, 23 and was named a Living Legend and most influential business leader in Palm Beach by the Palm Beach Illustrated. He served as the Orthopedic Surgeon to the White House from 2017 to 2021. He has published 193 peer- reviewed articles, 73 book chapters, 50 video productions and 9 books; most notably: Congenital Femoral Deficiency 2023, and Principles of Deformity Correction, Springer (2002, 2005).The CORA method of deformity analysis in this text has become the gold standard for deformity planning in orthopedics.

Dr. Paley developed over 100 surgical procedures including: SUPERhip, SUPERknee, SUPERankle, SHORDT, Paley-Weber patelloplasty, ulnarization, Paley Rotationplasty, modified Judet quadricepsplasty, Paley XUNION for CPT, MHE forearm correction, four-segment achondroplasia lengthening, and many others. He had had an interest in Perthes disease since 1989 when he first developed the method of articulated hip distraction for Perthes. He has also developed a method to reshape the femoral head using Femoral Head Reduction Osteotomy. He developed the Multiplier method of predicting leg length discrepancy and timing of epiphysiodesis, now available using the Android and iOS app Paley Growth Multiplier App. He was Professor of Orthopedics at University of Maryland 1987-2001. He was adjunct Professor of Orthopedic Surgery and consultant at the Hospital for Sick Children, University of Toronto, from 2010-2014. He currently holds an academic appointment as a Professor of Orthopedics at the University of Vermont and Florida Atlantic University. He sits on the Board of Governors of St. Mary's Medical Center. He has performed 25,000+ surgeries. Patients come to see him from all 50 states and over 100 countries. He is fluent, writes, reads, and lectures in six languages. He runs the Paley and unLIMBited Foundations and does mission trips around the world.

He lives with his wife Jennifer and stepson Daelan and has three grown children, Benjamin, Jonathan, and Aviva, and two grandchildren, Dalia and Jack. His hobbies include reading history, skiing, road and mountain biking, rock climbing, and scuba diving. Visit PaleyInstitute.org to learn more about Dr. Paley and the Paley Institutes.

Cathleen Raggio

Cathleen L. Raggio, M.D. specializes in general pediatric orthopedics, scoliosis and in the treatment of osteogenesis imperfecta and skeletal dysplasia and is the Co-Director of the Kathryn O. and Alan C. Greenberg Center for Skeletal Dysplasias at Hospital for Special Surgery.

Dr. Raggio completed her residency in orthopedic surgery at Hospital for Special Surgery and fellowship in pediatric orthopedic surgery at Alfred I. duPont Hospital for Children. Known worldwide throughout the medical community, Dr. Raggio performs basic science and clinical research on the etiology of scoliosis, osteogenesis imperfecta, osteoporosis, and skeletal dysplasias. Dr. Raggio has helped define the different types of OI, specifically type IX and the different drug treatment options using the mice models of OI.

She has served as Co-Chair of the International Research Conference in Annapolis and has served on the subsequent organizing committees.

Dr. Raggio is currently on the OI Foundation's Medical Advisory Council and has spoken at the biennial National Conferences.

Adalbert Raimann

Adalbert Raimann is paediatric endocrinologist at the Medical University of Vienna. Starting with basic research on bone and linear growth at Harvard Medical School / MGH, Adalbert's scientific interest focused on unmet clinical needs in rare bone disorders such as X-linked hypophosphatemia. Current projects aim to address clinical questions in in vitro cellular models with focus on musculoskeletal physiology in metabolic bone and growth disorders. Adalbert is active member of ISCBH, ECTS, NetsOs and the Austrian Society for Bone and Mineral Research.

Frank Rauch

Frank Rauch, MD, is a Professor of Paediatrics and clinician-scientist at the Shriners Hospital for Children and at McGill University in Montreal. He trained as a paediatrician at Cologne University, Germany. At Shriners Hospital and McGill University since 2001, his clinical activities and research program concentrate on bone health in children. He is the Medical Director of the Osteogenesis Imperfecta program and Director of the Clinical Biomedical Laboratory at Shriners Hospital, responsible for the molecular diagnosis of genetic bone disorders and for their medical treatment. Dr. Rauch has authored or coauthored more than 400 publications that have been cited more than 30,000 times.

Fernando Rivadeneira

I am Prof. Dr. Fernando Rivadeneira, M.D., Ph.D., a medical doctor and genetic epidemiologist, serving as Professor of Translational Genomics at Erasmus University Medical Center Rotterdam, The Netherlands. My research focuses on translating genomic discoveries into clinical applications, with an emphasis on musculoskeletal health. I integrate epidemiological, imaging, and genomic data within large population-based cohorts such as Generation R (children) and the Rotterdam Study (elderly). My team and I have significantly contributed to identifying genetic determinants of musculoskeletal traits using high-throughput technologies, collaborating in international GWAS consortia and utilizing resources like the UK Biobank. I co-lead the European Commission-funded "Genetics Factors of Osteoporosis" (GEFOS) consortium and have been involved in multiple EC Horizon projects. Recently, I chaired the "Genomics of Musculoskeletal Traits Translational Network" (GEMSTONE) Cost Action of the EC and received an ERC Advanced Grant for the "LEveraging GENomic Discoveries and skeletal phenotyping to improve osteoporosis patient cARE" (LEGENDARE) program.

Alex Robling

Dr. Robling is the Vincent H. Gattone II Professor and Chair of the Department Anatomy, Cell Biology & Physiology at the Indiana University School of Medicine. He received his PhD from the University of Missouri–Columbia, then went on to do a postdoctoral fellowship in biomechanics and genetics in the lab of Charles Turner (Dept. of Orthopaedic Surgery) at Indiana University. He completed a second postdoctoral fellowship in cell and molecular biology in the laboratory of Fred Pavalko (Dept. of Cellular & Integrative Physiol.) at IU. Following this fellowship, he accepted a faculty position in the Department of Anatomy & Cell Biology at IU. Dr. Robling's work is focused on mechanical signaling in bone cells, with particular interest in the Wnt pathway. He is the recipient of the ORS New Investigator Recognition Award, the ASBMR Young Investigator Award, the John Haddad Young Investigator Award, the AIMM Investigator Award, the Harold Frost Young Investigator Award, and the ASBMR Fuller Albright Award. He serves on several Boards of Directors and journal editorial boards, and is currently the PI on several grants from the NIH and the VA. He has over 150 peer-reviewed publications and also teaches gross anatomy to the first year medical students at IU.

Babak Saboury

Dr. Babak Saboury, MD, MPH, is an Oncoradiologist and Nuclear Medicine physician specializing in radiopharmaceutical therapy. His clinical practice and research over the past decade have centered on image-guided personalized medicine, quantitative medical imaging, radiopharmaceutical therapy, and public health aspects of the healthcare system. He earned his MD and MPH from Tehran University of Medical Sciences and went on to direct the Quantitative Medical Imaging Laboratory at the University of Pennsylvania. Dr. Saboury completed his Diagnostic Radiology and Integrated Nuclear Medicine residency training at the University of Maryland Medical Center (UMMC) and is also board certified in clinical informatics.

He joined the National Institutes of Health as a clinician scientist and Chief Clinical Data Science Officer, where he advanced precision dosimetry and radiopharmaceutical therapy, authoring numerous studies, including investigations into sodium fluoride PET imaging and advanced computational imaging in the study of metabolic bone diseases. Currently, Dr. Saboury is the physician founder and Chief Innovation Officer at United Theranostics, and Co-founder and President of the Institute of Nuclear Medicine (INM).

Ravi Savarirayan

Ravi Savarirayan is consultant clinical geneticist at Victorian Clinical Genetics Services, Professorial fellow at the University of Melbourne, and Group leader (Molecular Therapies at Murdoch Children's Research Institute, Victoria, Australia.

Professor Savarirayan received his MBBS from the University of Adelaide, Australia in 1990 and became a Fellow of the Royal Australasian College of Physicians in 1997. He was certified as a specialist in Clinical Genetics by the Human Genetics Society of Australasia in 1998 and was awarded his Doctor of Medicine from the University of Melbourne in 2004. He was awarded the Fulbright Professional Scholarship for Australia in 1998, and took this up at University of California, Los Angeles (UCLA).

Professor Savarirayan's primary research focus is on inherited disorders of the skeleton causing short stature, arthritis, and osteoporosis. He has published over 230 peer-reviewed articles and received over $35M in research funding, collaborating with researchers from 40 countries.

His current clinical trial activities are pioneering disruptive new therapies for the treatment of genetic disorders. He was the global lead investigator of the clinical development program that identified vosoritide as the first precision therapy for children with achondroplasia.

He was recently named one of the 30 "Brilliant minds" of the Murdoch Children's Research Institute over the past 30 years, was awarded the Institute's research excellence award in 2020, and is an NHMRC Leadership Fellow.

Oliver Semler

Prof. Dr. Oliver Semler is head of the department of rare skelettale diseases in childhood at the Children´s Hospital of the University Cologne, Germany and Professor of Paediatrics.

Prof. Dr. Semler studied medicine at the universities in Cologne and Freiburg and spent some time in Australia, South Africa and Canada. He completed his thesis on 'Surgical treatment of femur fractures in Osteogenesis imperfecta' at the university Heidelberg and finished his PhD in paediatrics with the thesis 'Translationale research in Osteogenesis imperfecta: From Pathophysiology to personalized treatment'.

Prof. Dr. Semler is certified as paediatric rheumatologist and pediatric endocrinologist and diabetologist and focusses clinical and scientifically on different skelettale dysplasia's. His main interest is the improvement and quantification of mobility and muscle function and the development of new medical treatments in rare bone diseases. He is Principal Investigator in a number of clinical trials and partner in international research networks. He is part of a translational scientific research group elucidating the pathomechanisms in Osteogenesis imperfecta and other diseases affecting skeletal development. He published more than 90 peer-reviewed articles and book chapters and was awarded with numerous awards like the Young Investigator Award of the European Society of Pediatric Endocrinology and with the Eva Luise Köhler Forschungspreis für Seltene Erkrankungen..

Annegreet Vlug

Annegreet Vlug practices as an internist-endocrinologist in the Jan van Goyen Medical Center and OLVG Hospital in Amsterdam. After training in Internal Medicine in Leiden and Amsterdam, she specialized in osteoporosis and bone disease during a clinical fellowship at the Erasmus Medical Center in Rotterdam. She received her PhD on the neuroendocrine regulation of human bone metabolism in 2015 from the University of Amsterdam and continued with a postdoc on human bone marrow adiposity in the lab of Clifford Rosen in Maine, USA. Currently she is a senior researcher in the Center for Bone Quality in Leiden continuing her research on human bone marrow adiposity, muscle and bone in addition to clinical studies on osteoporosis and menopause. She was elected president of the Ducth Society for Calcium and Bone metabolism in 2023 and serves on multiple other national and international committees from the European Calcified Tissue Society, the European Society for Endocrinology, and the International Bone Marrow Adiposity Society among others and represents the American Society for Bone and Mineral Research as a global ambassador.

Kate Ward

Kate is Professor of Global Musculoskeletal Health at MRC Lifecourse Epidemiology Centre, University of Southampton and an Honorary Senior Fellow at MRC Unit The Gambia at London School of Hygiene and Tropical Medicine. She co-leads the Sub-Saharan Africa Musculoskeletal Network which focusses on capacity building for musculoskeletal research. Kate directed the NIHR Global Health Nutrition Group, which was a collaboration across Burkina Faso, Ghana, South Africa and the UK (2018-2022). Kate's group is based in The UK and The Gambia where her research focusses on how to achieve and maintain functional ability to ensure healthy bone and muscle ageing in Africa and the UK. She is President of the UK Bone Research Society. Kate is also Associate Editor of Osteoporosis International, a member of the International Osteoporosis Foundation Committee for Scientific Advisors and Co-Chair of the American Society for Bone and Mineral Research Global Ambassador Committee.

Leanne Ward

Dr. Leanne Ward is a Professor of Paediatrics in the Faculty of Medicine at the University of Ottawa (Canada) where she holds a Senior Research Chair in Paediatric Bone Disorders. Dr. Ward is the Scientific Director of The Ottawa Paediatric Bone Health Research Group, The Medical Director of the Paediatric Bone Health-Osteology Clinic at the Children's Hospital of Eastern Ontario (CHEO), and a Paediatric Endocrinologist-Osteologist in the CHEO Division of Endocrinology. In 2014, she founded The Canadian Consortium for Children's Bone Health (a national network that fosters health professional education in childhood-onset bone disorders) and The Canadian Alliance for Rare Disorders of the Skeleton (a patient advocacy initiative). Dr. Ward's research is dedicated to the diagnosis and treatment of paediatric bone disorders including primary and secondary osteoporosis, skeletal dysplasias, and heritable forms of rickets. Her program has a particular focus on skeletal health outcomes quantified through central skeletal imaging, and the study of novel drugs to mitigate the functional consequences of rare bone diseases. The Ward lab's signature is local-to-global collaborative engagement with clinicians, researchers and the patient community in key areas that span orthopedics, genetics, imaging, endocrinology, allied health, biomedical statistics and clinical trial operations. In 2019, Dr. Ward was named a Fellow of the American Society of Bone and Mineral Research, an award in recognition of significant lifetime contributions to bone and mineral science.